TSO3 Inc

TSO3 — Investor Presentation (December 2015)

33 slides from TSO3's investor presentation, December 2015

  1. Slide 1: Creating The Improved Standard In Healthcare Sterile Reprocessing

    Creating The Improved Standard In Healthcare Sterile Reprocessing™ December 2015 Corporate Presentation TSX:TOS

  2. Slide 2: Our Vision

    2 Our Vision “To Create the Improved Standard in Healthcare Sterile ReprocessingTM”

  3. Slide 3: Company Overview

    3 Company Overview Past Current • Founded 1998 • New Sterilizer FDA 510(k) • Design and Manufacture Cleared – December 2014 Low Temperature • Financing Completed Sterilizers for Medical – March 5, 2015 Devices • Distribution Agreement Signed: • IPO 2001 – GETINGE Infection Control • TSX: TOS – March

  4. Slide 4: What We Do… Enable Better Healthcare

    4 What We Do… - Enable Better Healthcare By delivering Low Temperature Sterilization Systems that offer:  Reliable  Low cost  Rapid turnaround  Compatible  Environmentally Friendly  Efficient  High Volume Solutions for simple and complex reusable medical devices that cannot withstand other ha

  5. Slide 5: Why Low Temperature Sterilization? (market drivers)

    5 Why Low Temperature Sterilization? (market drivers)

  6. Slide 6: Market Drivers

    6 Market Drivers 53% Increase Aging Population 65 yrs + 45 to 64 15 to 44 - 15 yrs 2001 2005 2010 2015 2020

  7. Slide 7: Age Impact on Demand and Type of Surgery

    7 Age Impact on Demand and Type of Surgery Open Surgery Minimally Invasive Surgery (MIS) 88% of ophthalmology surgeries Percentage of 70% of cardiothoracic surgeries procedures (average) by age 65% of urology surgeries 60% of general surgeries 45 45 55 55 65 65 75 75

  8. Slide 8: MIS Procedures

    8 MIS Procedures Increasingly used and finding new applications everyday Neurosurgery Gynaecology Cardiology Orthopaedic Urology Gastrointestinal Pulmonary medicine MIS 30 million + surgeries in US/year MIS Devices Complex and Delicate

  9. Slide 9: MIS Devices Require Low Temperature Sterilization

    9 MIS Devices Require Low Temperature Sterilization

  10. Slide 10: Technology Platform: Global Market Overview

    10 Global Market Overview / Low Temperature Sterilization Capital Equipment (Sterilizers) Placements Technology Platform ETO – Low Temperature Gas Sterilizers in Hospitals: • ~30,000 installed worldwide • Life span ~ 10 years • Replacement business: 3,000 units/year H2O2  Total Replacement Value $4

  11. Slide 11: STERIZONE VP4 Sterilizer

    11 STERIZONE® VP4 Sterilizer The NEXT GENERATION LOW TEMPERATURE STERILIZER The ONLY Two or More Sterilant Sterilizer cleared in the USA SUPERIOR Claims to any Cleared Device Vaporizing technology STERIZONE® VP4 Sterilizer • Vaporizer temperature: 120°C • Unique cycle intended for • Vaporizes and in

  12. Slide 12: Cleared Claims (USA – December 2014)

    12 Cleared Claims (USA – December 2014) STERIZONE® VP4 Sterilizer • Broadest claims in industry; More devices and Greatest flexibility of load configurations  Flexible, Rigid and General instruments in the same load • Largest quantity of devices in Load in Industry • Highest gross weight available

  13. Slide 13: Canada and ROW Sterilizer Claims

    13 STERIZONE® Sterilizer Claims Inside Length Diameter #Single channel Cycle 1 ≥ 1.0 mm ≤ 850 mm flexible endoscopes Rigid channel CANADA devices including ≥ 0.7 mm ≤ 500 mm AND ROW Cycle 2 single channel and double rigid channel ≥ 2.0 mm ≤ 575 mm (TODAY) endoscopes Multi-Channel Cycle 3 ≥ 1,1 mm ≤

  14. Slide 14: USA Sterilizer Claims

    14 STERIZONE® Sterilizer Claims Inside MIXED LOADS Length Diameter Single channel flexible ≥ 1.0 mm ≤ 850 mm endoscopes USA Single Cycle ≥ 0.7 mm ≤ 500 mm Rigid channeled devices (Cycle 1) including single channel and double rigid ≥ 2.0 mm ≤ 575 mm channel endoscopes

  15. Slide 15: Canada (applied for) Claims

    15 STERIZONE® Sterilizer Claims Inside Length Diameter Single channel Cycle flexible ≥ 1.0 mm ≤ 850 mm 1 endoscopes Rigid channel ≥ 0.7 mm ≤ 500 mm devices including CANADA single channel and Cycle double rigid (applied for) 1 channel ≥ 2.0 mm ≤ 575 mm endoscopes Multi-Channel Cycle 1 Cycle flexible

  16. Slide 16: Customer Benefits

    16 Customer Benefits  Single cycle, for all loads Ease of use / Reduction of operator error / Enhanced quality  Utilizable three shelf racks Makes the STERIZONE® VP4 Sterilizer (4.3 cu’) chamber fully usable - Most instruments per load (Reduced operating cost/Faster turnaround)  Least load restri

  17. Slide 17: Throughput Defined

    17 Throughput Defined One load vs. three… • Mixed loads • Greater quantity • Greater complexity • Reduced time • Reduced cost

  18. Slide 18: Reprocessing Areas in Hospitals

    18 Reprocessing Areas in Hospitals CSSD - STERILE GI – High Level Disinfected

  19. Slide 19: Margin of safety: Spaulding Classification

    19 Reprocessing The What to DO ... and When ... Spaulding Classification Body Contact Disinfection FDA Device Requirements Class LOWEST Intact skin Low level Non-critical disinfection Margin of safety Mucous High level Semi-critical membranes disinfection Sterile body cavity Sterilization Critical H

  20. Slide 20: The Superbug Problem

    20 The Superbug Problem What is it ? SUPERBUG = Antimicrobial Resistance Increasingly a Problem “….CRE bacteria have become resistant to most available antibiotics.— one report cites they can contribute to death in up to 50% of patients who become infected.” Call to Action Centers for Disease Contro

  21. Slide 21: Increased Importance of Technology

    21 Increased Importance of Technology Diagnostic instruments (mucous membranes) are being repurposed for use in surgical (sterile body cavity) Endoscopic Retrograde procedures Cholangiopancreatography High Level Disinfection  STERILIZATION…? (ERCP)

  22. Slide 22: Potential ERCP Opportunity

    22 Potential “ERCP” Opportunity  Sterilization as a standard of practice ... IMPACT 650,000 >1000 use locations procedures annually (potential placements) Spill over to other scopes ???... Colonoscopes, gastroscopes ,etc.

  23. Slide 23: Opportunity Expansion

    23 Opportunity Expansion Our Data TSO3 in-house data supports feasibility of pursuing enhanced claim to existing clearance (not a new clearance) for high risk flexible endoscopes

  24. Slide 24: The Only Company to Obtain US Clearance on Complex Multi-Channeled Flexible Scopes

    24 TSO3 : The Only Company to Obtain US Regulatory Clearance on Complex Multi-Channeled Flexible scopes Indications for Use 2009 extended claims 510(k): K090636 Device Name: TSO3 Ozone Sterilizer, model 125L Indications for Use: TSO3 125L Ozone Sterilizer has the ability to sterilize successfully pa

  25. Slide 25: TSO3 gets FDA okay for expanded claims

    25 TSO3 gets FDA okay for expanded claims December 4, 2009 (TSX:TOS) has received the green light from the FDA to expand the intended claims of its STERIZONE® 125L Sterilizer, including sterilization of packaged, multi-channel flexible endoscopes, such as colonoscopes, gastroscopes, bronchoscopes, u

  26. Slide 26: Go To Market Strategy

    GO TO MARKET STRATEGY =~ @ \ \

  27. Slide 27: Go to Market Strategy

    27 Go to Market Strategy - CHANNEL - Leverage available Sales and Service channels  Non-exclusive Agreements  Maintain Positioning and Pricing Control  Obtain contracts positions with:  Group Purchasing Organizations (GPO) and Integrated Delivery Network (IDN) contracts  Utilize established ser

  28. Slide 28: Getinge Infection Control

    28 Getinge Infection Control TSO3 ENTERS INTO FIRST Associates: 3,089 COMMERCIAL AGREEMENT FOR Revenue: SEK 5,4 billion = USD 0.650 M STERIZONE® VP4 STERILIZER Global Headquarters: Getinge, Sweden Québec City, March 6, 2015 – TSO3 Inc. Sales Companies: 36 (TSX: TOS) ("TSO3" or the "Corporation") Man

  29. Slide 29: Emerging Support Materials

    29 Emerging Support Materials

  30. Slide 30: Short Term Efforts

    30 Short Term Efforts TSO3 will IMMEDIATELY…  Place units in targeted strategic accounts  Open US customer training and distribution facility  Rationalize product to STERIZONE® VP4 Sterilizer in North America  Sign Group Purchasing /Integrated delivery networks (IDN) contracts (USA)  Increase l

  31. Slide 31: Financial Situation – As of September 30, 2015

    31 Financial Situation – As of September 30, 2015 September 30 (000’s) Total Sales Revenue 1,436 Liquidities 12,207 Inventories 1,514 Total Assets 18,064 Equity 16,569 Monthly Burn Rate – LTM 638 Outstanding Shares (September 2015) 83,264 Outstanding Options and Warrants (September 2015) 13,410 31

  32. Slide 32: Thank you!

    32 Thank you!

  33. Slide 33: © TSO3 Inc., 2015

    33 © TSO3 Inc., 2015 All rights reserved for all countries. No part of this publication may be reproduced or translated in any form or by any means, without the prior written permission of TSO3 Inc. - STERIZONE® are registered trademarks of TSO3 Inc. U.S. Pat. No. 6,589,479 / 7,582,257 / 7,588,720 /

TSO3 — Investor Presentation (December 2015) on 6ix